GlassScriptPhysician profile
James G Harold
NPI 1760543482
$120,423.09
in general payments reported to CMS, 2019-2025
27 companies · $5,737 in 2025
The $5,737 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $7,315 · 2021: $18K · 2022: $26K · 2023: $30K · 2024: $1,183 · 2025: $5,737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $9,832 · Travel and Lodging: $2,225 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,835.00 |
| Food and Beverage | $9,832.21 |
| Travel and Lodging | $2,225.01 |
| Education | $153.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $47,231.67 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $35,727.89 | 2019-2025 | Austedo, Uzedy, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $14,483.43 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $13,738.27 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Neurocrine Biosciences, INC. | $1,797.36 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,542.62 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,278.27 | 2020-2025 | Caplyta |
| Abbvie INC. | $1,157.94 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $805.61 | 2019-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $564.65 | 2023-2025 | Auvelity |
| Indivior INC. | $552.62 | 2019-2025 | Perseris, Sublocade |
| Lundbeck LLC | $395.66 | 2019-2025 | Rexulti, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $255.23 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $227.44 | 2019-2025 | Trintellix |
| Allergan, INC. | $193.10 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $104.32 | 2019 | |
| Eisai INC. | $71.00 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $69.72 | 2023 | Quviviq |
| Luye Pharma (USA) LTD. | $40.59 | 2025 | Erzofri Extended-Release |
| Tempus Ai, INC | $40.50 | 2025 | Tempus Pixel |
| Tris Pharma INC | $33.66 | 2025 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $27.37 | 2019 | |
| Almatica Pharma LLC | $17.78 | 2025 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $17.28 | 2025 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $16.51 | 2019 | |
| Noven Therapeutics, LLC | $16.39 | 2023 | Secuado |
| Janssen Biotech, INC. | $16.21 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Harold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.